PT - JOURNAL ARTICLE AU - Raúl Méndez AU - Paula González-Jiménez AU - Ana Latorre AU - Leyre Serrano AU - Luis Alberto Ruiz AU - Rafael Zalacaín AU - Pedro Pablo España AU - Ane Uranga AU - Catia Cillóniz AU - Antoni Torres AU - Rosario Menéndez TI - Early profiling of low-risk SARS-CoV-2 pneumonia for ward allocation AID - 10.1183/13993003.congress-2021.PA3659 DP - 2021 Sep 05 TA - European Respiratory Journal PG - PA3659 VI - 58 IP - suppl 65 4099 - http://erj.ersjournals.com/content/58/suppl_65/PA3659.short 4100 - http://erj.ersjournals.com/content/58/suppl_65/PA3659.full SO - Eur Respir J2021 Sep 05; 58 AB - Introduction: The new coronavirus causing COVID-19 has spread worldwide, leading to a shortage of ICU and ward beds, thereby prompting the need to triage mild vs severe pneumonia. The objective of our study is to identify patients with low-risk COVID-19 pneumonia who do not require ICU admission and/or do not die during hospitalization, based on analytical and clinical data obtained in the initial evaluation.Methods: To this end, a multicenter cohort was defined in 4 hospitals with 1274 hospitalized patients. The cohort was stratified into two groups: (1) low-risk patients (hospitalized pneumonia that does not require ICU admission or die during hospitalization) and (2) severe pneumonia (direct or subsequent ICU admission and/or death). Demographic variables, analytics, and lower ATS/IDSA criteria were collected. A univariate study was conducted and, the variables found as significant, were introduced in a multivariate analysis of logistic regression.Results: Five independent associated factors were identified as predictors of no ICU requirement and/or death: <3 IDSA/ATS minor criteria (OR 0.23, 95% CI 0.15- 0.37), SpO2/FiO2 > 450 (OR 0.23, 0.15-0.36), CRP <60 mg/L (OR 0.45, 0.29-0.72), lymphocyte > 723 cells/mL (OR 0.54, 0.36-0.81) and urea <40 mg/dL (OR 0.65, 0.43-0.99), with an AUC of 0.80 (0.77-0.84).Conclusions: In conclusion, early identification of low-risk SARS-CoV-2 pneumonia is feasible based on initial biochemical findings and using lower ATS/IDSA criteria. This is useful for the quickly decision of hospital admission when there are different hospitalization alternatives.Funding: Instituto de Salud Carlos III (COV20/00385).FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3659.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).